Gerd Wohlfahrt

Nuvisan (Germany) — Germany

Biochemistry, Genetics and Molecular Biology · Life Sciences

27h-index3.0kcitations77works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Estrogen and related hormone effects(12), Enzyme Catalysis and Immobilization(11), Prostate Cancer Treatment and Research(11), Fibroblast Growth Factor Research(9), Computational Drug Discovery Methods(7)

Publications77 total

Abstract 6978: Discovery and characterization of BAY-805, a potent and selective DUB inhibitor of ubiquitin specific peptidase USP21
Cancer Research·2025
Data from First-in-Class Small Molecule to Inhibit CYP11A1 and Steroid Hormone Biosynthesis
2023Open Access
Data from First-in-Class Small Molecule to Inhibit CYP11A1 and Steroid Hormone Biosynthesis
2023Open Access
Supplementary Data from First-in-Class Small Molecule to Inhibit CYP11A1 and Steroid Hormone Biosynthesis
2023Open Access
Supplementary Table S1 and Figures S1-S7 from ODM-203, a Selective Inhibitor of FGFR and VEGFR, Shows Strong Antitumor Activity, and Induces Antitumor Immunity
2023Open Access
Data from ODM-203, a Selective Inhibitor of FGFR and VEGFR, Shows Strong Antitumor Activity, and Induces Antitumor Immunity
2023Open Access
Supplementary Table S1 and Figures S1-S7 from ODM-203, a Selective Inhibitor of FGFR and VEGFR, Shows Strong Antitumor Activity, and Induces Antitumor Immunity
2023Open Access
Supplementary Data from First-in-Class Small Molecule to Inhibit CYP11A1 and Steroid Hormone Biosynthesis
2023Open Access
Data from ODM-203, a Selective Inhibitor of FGFR and VEGFR, Shows Strong Antitumor Activity, and Induces Antitumor Immunity
2023Open Access
Discovery and Characterization of BAY-805, a Potent and Selective Inhibitor of Ubiquitin-Specific Protease USP21
Journal of Medicinal Chemistry·2023· 24 citedOpen Access
First-in-Class Small Molecule to Inhibit CYP11A1 and Steroid Hormone Biosynthesis
Molecular Cancer Therapeutics·2022· 21 citedOpen Access
Abstract 1143: Evaluation of AU-18069, a novel small molecule CBP/p300 bromodomain inhibitor for the treatment of cancers
Cancer Research·2021· 1 cited
Abstract 1250: ODM-208, a novel, small-molecule CYP11A1 inhibitor, demonstrates strong inhibition of steroid biosynthesis and antitumor activity in castration-resistant prostate cancer (CRPC) model
Cancer Research·2021
Discovery and characterization of ORM‐11372, a novel inhibitor of the sodium‐calcium exchanger with positive inotropic activity
British Journal of Pharmacology·2020· 14 citedOpen Access
Abstract 1754: First in class orally bioavailable BETBRD degraders
Cancer Research·2020
Abstract 1753: Targeting cancer with selective cbp/p300 bromodomain inhibitors
Cancer Research·2020· 2 cited
CYP11A1 inhibition as a therapeutic approach for the treatment of castration resistant prostate cancer
Endocrine Abstracts·2019
SUN-LB002 CYP11A1 Inhibition as a Therapeutic Approach for the Treatment of Castration Resistant Prostate Cancer
Journal of the Endocrine Society·2019· 4 citedOpen Access
ODM-203, a Selective Inhibitor of FGFR and VEGFR, Shows Strong Antitumor Activity, and Induces Antitumor Immunity
Molecular Cancer Therapeutics·2018· 33 citedOpen Access
CYP11A1 inhibition as a therapeutic approach for the treatment of castration resistant prostate cancer
Annals of Oncology·2018· 1 citedOpen Access
page 1 of 4Next →

Frequent Co-authors

Dietmar Schomburg(9), Riikka Oksala(6), Anu Koivula(6), Vesa M. Olkkonen(6), Reetta Riikonen(5), Pekka Kallio(5), Tuula T. Teeri(5), Subhendu Mukherjee(5), Murali Ramachandra(5), Anu Moilanen(5), T. Alwyn Jones(4), Vigneshwari Subramanian(4), Peteris Prūsis(4), Rajeev Goswami(4), Jwala Nagaraj(4), Petteri Rummakko(4), Meri Ramela(4), Christina Divne(3), Kathleen Piens(3), Marc Claeyssens(3)